The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease. [electronic resource]
Producer: 20130829Description: 102-14 p. digitalISSN:- 1559-1174
- Alzheimer Disease -- genetics
- Amyloid beta-Peptides -- metabolism
- Amyloid beta-Protein Precursor -- genetics
- Animals
- Astrocytes -- drug effects
- Disease Models, Animal
- Female
- Frontal Lobe -- pathology
- Glucagon-Like Peptide 1 -- analogs & derivatives
- Hypoglycemic Agents -- pharmacology
- Insulin Receptor Substrate Proteins -- metabolism
- Insulin Resistance
- Liraglutide
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Transgenic
- Microglia -- drug effects
- Mutation, Missense
- Neuroprotective Agents -- pharmacology
- Phosphorylation -- drug effects
- Plaque, Amyloid -- prevention & control
- Presenilin-1 -- genetics
- Protein Processing, Post-Translational -- drug effects
- Protein Transport -- drug effects
- Receptor, Insulin -- metabolism
- Signal Transduction -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.